MOLN
MOLN clinical trials: MOLECULAR PARTNERS AG
Every trial on ClinicalTrials.gov where MOLECULAR PARTNERS AG is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 16
- Trials linked
- 10
- As lead sponsor
- 6
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
MOLN on the catalyst calendar · MOLN registry changes
- Primary completion Sep 2028Sponsor estimatePhase 1/Phase 2NCT07278479Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid TumorsMolecular Partners AG · Large Cell Neuroendocrine CarcinomaRecruitingMOLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 29, 2026ActualPhase 1NCT05673057Study of MP0533 in Patients Acute Myeloid Leukemia or Myelodysplastic SyndromeMolecular Partners AG · LeukemiaCompletedMOLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 19, 2024ActualPhase 1NCT05098405First-in-human Safety and Tolerability of MP0317 in Patients With Relapsed/Refractory Advanced Solid TumorsMolecular Partners AG · Advanced Malignant Solid TumorTerminatedMOLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 30, 2019ActualPhase 1NCT03418532MP0250 DARPin® Protein Plus Osimertinib in Patients With EGFR-mutated NSCLCMolecular Partners AG · EGFR-mutated NSCLC (Disorder)TerminatedMOLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 27, 2022ActualPhase 1NCT04049903Study to Investigate the Safety, Blood Levels and Activity of MP0310 in Patients With Advanced Solid TumorsMolecular Partners AG · Advanced Solid TumorCompletedMOLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 6, 2022ActualPhase 1NCT04870164Safety, Tolerability and PK of Ensovibep (MP0420 - a New Candidate With Potential for Treatment of COVID-19)Molecular Partners AG · COVID-19TerminatedMOLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 13, 2021ActualPhase 1NCT03084926First-in-human Study to Investigate Safety, Blood Levels and Activity of MP0274 in Cancer Patients With HER2-positive Solid TumorsMolecular Partners AG · NeoplasmsCompletedMOLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Aug 20, 2021ActualPhase 2NCT04834856Viral Clearance, PK and Tolerability of Ensovibep in COVID-19 PatientsMolecular Partners AG · Covid19CompletedMOLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 12, 2020ActualPhase 1/Phase 2NCT03136653A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple MyelomaMolecular Partners AG · Multiple Myeloma in RelapseCompletedMOLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 20, 2018ActualPhase 1/Phase 2NCT02194426First-in-human Study to Investigate the Safety, Tolerability and Blood Levels of the Test Drug MP0250 in Cancer PatientsMolecular Partners AG · NeoplasmsCompletedMOLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2028Sponsor estimatePhase 2NCT07036380MP0317 in Combination With Chemoimmunotherapy in First Line Treatment for Patients With Advanced Biliary Tract CarcinomaCentre Hospitalier Universitaire de Besancon · Advanced Biliary Tract CarcinomaRecruitingMOLNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 18, 2021ActualPhase 2/Phase 3NCT04828161A Dose Finding, Efficacy and Safety Study of Ensovibep (MP0420) in Ambulatory Adult Patients With Symptomatic COVID-19Novartis Pharmaceuticals · COVID-19TerminatedNVSLeadMOLNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Feb 23, 2022ActualPhase 3NCT05780463MP0420 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)National Institute of Allergy and Infectious Diseases (NIAID) · COVID-19CompletedMOLNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 6, 2022ActualPhase 3NCT04501978ACTIV-3: Therapeutics for Inpatients With COVID-19National Institute of Allergy and Infectious Diseases (NIAID) · Covid19
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 2010ActualPhase 1NCT01086761Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular DegenerationAllergan · Wet Age-Related Macular DegenerationTerminatedABBVLeadMOLNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2010ActualPhase 1NCT01042678Study of MP0112 Intravitreal Injection in Patients With Diabetic Macular EdemaAllergan · Diabetic Macular EdemaTerminatedABBVLeadMOLNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 16 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner